Hospital
Hendersonville Hospital Corporation
Hendersonville Hospital Corporation was paid $23.54M by Medicaid between Jan 2018 and Dec 2024, across 76 billing codes. Its largest line is 99283, emergency room visit (moderate) — 47% of everything it billed.
33Billing provider infoHENDERSONVILLE HOSPITAL CORPORATION
HENDERSONVILLE, TN 37075
HENDERSONVILLE, TN 37075
33aNPI1538114434assigned 05/23/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.54M
24GClaims332,167
24DCodes billed76
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#11 of 71
Median peer was paid$6.96M
This provider vs. median3.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,454 | $3.54M | |
| 2019 | 47,253 | $3.48M | |
| 2020 | 40,350 | $2.73M | |
| 2021 | 51,915 | $3.43M | |
| 2022 | 60,599 | $3.99M | |
| 2023 | 56,830 | $3.78M | |
| 2024incomplete | 30,766 | $2.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 47% | 41,367 | 38,162 | $11.09M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 46% | 40,082 | 35,040 | $10.83M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.7% | 22,678 | 19,737 | $1.12M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,486 | 5,666 | $84K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 497 | 479 | $84K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,772 | 1,656 | $57K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 699 | 208 | $46K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 161 | 127 | $41K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,449 | 5,484 | $35K |
| 36415 | Collection of venous blood by venipuncture | <1% | 20,998 | 18,124 | $31K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 843 | 798 | $31K |
| G0378 | Hospital observation service, per hour | <1% | 84 | 49 | $25K |
64 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,320 | $18K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 112 | $9K |
| 80053 | Comprehensive metabolic panel | <1% | 31,545 | $7K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 426 | $5K |
| 85027 | <1% | 37,005 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,407 | $4K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 21 | $4K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,231 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,220 | $2K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 24 | $2K |
| 84484 | <1% | 4,414 | $1K | |
| 85610 | <1% | 4,214 | $1K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,099 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,925 | $981.89 |
| 81001 | <1% | 19,962 | $778.01 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 40 | $751.61 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,521 | $454.96 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,041 | $383.98 |
| 87081 | <1% | 1,255 | $328.07 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,553 | $250.74 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 552 | $158.19 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,078 | $137.74 |
| 87070 | <1% | 938 | $126.34 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,013 | $106.06 |
| 87807 | <1% | 1,185 | $89.47 | |
| 83690 | <1% | 5,676 | $65.57 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,994 | $54.44 |
| 84703 | <1% | 2,031 | $44.68 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,802 | $38.62 |
| 81025 | <1% | 4,406 | $34.47 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 16 | $25.30 |
| 87040 | <1% | 217 | $22.94 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,185 | $19.24 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 641 | $15.12 |
| 83735 | <1% | 3,796 | $14.88 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 180 | $12.79 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,007 | $10.80 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 620 | $9.67 |
| 85730 | <1% | 2,075 | $7.50 | |
| 82150 | <1% | 543 | $5.83 | |
| 82248 | <1% | 766 | $4.84 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 138 | $2.87 |
| 81003 | <1% | 541 | $2.70 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 29 | $0.00 |
| 83880 | 0% | 789 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 55 | $0.00 |
| 83605 | 0% | 482 | $0.00 | |
| 85652 | 0% | 61 | $0.00 | |
| 82550 | 0% | 77 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 90 | $0.00 |
| 74019 | 0% | 15 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 26 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 12 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 39 | $0.00 |
| 82553 | 0% | 31 | $0.00 | |
| 83874 | 0% | 31 | $0.00 | |
| 87581 | 0% | 20 | $0.00 | |
| 87486 | 0% | 20 | $0.00 | |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 427 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 29 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 28 | $0.00 |
| 87186 | 0% | 15 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 20 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSOLOMON, DAVID (CFO)